CDK7 inhibition for treating small cell lung cancer

INDICATION: Lung cancer

Inhibiting CDK7, a cell cycle regulator, could treat small cell lung cancer (SCLC) and enhance the efficacy of checkpoint inhibition and chemotherapy. In mouse and human SCLC cell lines, a CDK7 inhibitor tool compound induced proinflammatory cytokine production, reduced cell growth and induced cell death. In mice with SCLC, the CDK7 inhibitor reduced tumor growth and extended survival. Combining the compound with an anti-PD-1 mAb, or with the mAb plus chemotherapy, led to greater reductions in tumor burden and further improved survival compared with any of the treatments alone or chemotherapy plus the mAb...